Rituximab biosimilar - JHL Biotech

Drug Profile

Rituximab biosimilar - JHL Biotech

Alternative Names: JHL 1101

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator JHL Biotech
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 04 Apr 2017 The Chinese Food and Drug Administration accepts Clinical Trial application for Rituximab biosimilar for phase I and phase III clinical trials in Non-Hodgkin's lymphoma
  • 04 Apr 2017 JHL Biotech plans phase I and phase III trials in Non-Hodgkin's lymphoma in China
  • 31 Mar 2017 Rituximab biosimilar - JHL Biotech is available for licensing as of 18 May 2016. http://www.jhlbiotech.com/index.php
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top